Reviewing Acasti Pharma Inc. (ACST)’s and VIVUS Inc. (NASDAQ:VVUS)’s results

Acasti Pharma Inc. (NASDAQ:ACST) and VIVUS Inc. (NASDAQ:VVUS) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acasti Pharma Inc. N/A 0.00 N/A -1.22 0.00
VIVUS Inc. 56.89M 0.97 42.52M -3.98 0.00

Table 1 demonstrates Acasti Pharma Inc. and VIVUS Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Acasti Pharma Inc. 0.00% 0% 0%
VIVUS Inc. -74.74% 182.8% -15.1%

Insider & Institutional Ownership

Roughly 0.64% of Acasti Pharma Inc. shares are held by institutional investors while 18.3% of VIVUS Inc. are owned by institutional investors. Acasti Pharma Inc.’s share held by insiders are 8.49%. Insiders Comparatively, held 0.7% of VIVUS Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acasti Pharma Inc. -11.36% -35.29% 14.73% -3.43% -57.56% -31.36%
VIVUS Inc. 3.53% -25.82% -37.79% -66.7% -52.05% -41.7%

For the past year Acasti Pharma Inc. has stronger performance than VIVUS Inc.


Acasti Pharma Inc. beats on 5 of the 9 factors VIVUS Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.